Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on breast cancer medicines, has scheduled its fourth quarter and full year 2024 financial results conference call for Tuesday, March 25, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast to discuss corporate and financial results. Investors can access the webcast through the investor relations section of Atossa's website. For telephone access, U.S. callers should dial 1-800-836-8184, while international participants can dial 1-646-357-8785. The conference call name is 'Atossa Therapeutics Business Update'. A 30-day replay will be available on the company's website following the call.
Atossa Therapeutics (NASDAQ: ATOS), un'azienda biofarmaceutica in fase clinica focalizzata sui farmaci per il cancro al seno, ha programmato una conferenza telefonica per presentare i risultati finanziari del quarto trimestre e dell'intero anno 2024 per martedì 25 marzo 2025, alle 8:30 ET.
L'azienda ospiterà sia una conferenza telefonica che una trasmissione audio in diretta per discutere i risultati aziendali e finanziari. Gli investitori possono accedere alla trasmissione tramite la sezione relazioni con gli investitori del sito web di Atossa. Per l'accesso telefonico, i chiamanti statunitensi devono comporre il numero 1-800-836-8184, mentre i partecipanti internazionali possono chiamare il numero 1-646-357-8785. Il nome della conferenza telefonica è 'Aggiornamento Aziendale di Atossa Therapeutics'. Una registrazione di 30 giorni sarà disponibile sul sito web dell'azienda dopo la chiamata.
Atossa Therapeutics (NASDAQ: ATOS), una empresa biofarmacéutica en etapa clínica centrada en medicamentos para el cáncer de mama, ha programado una conferencia telefónica para presentar los resultados financieros del cuarto trimestre y del año completo 2024 para el martes 25 de marzo de 2025, a las 8:30 a.m. ET.
La empresa llevará a cabo tanto una conferencia telefónica como una transmisión de audio en vivo para discutir los resultados corporativos y financieros. Los inversores pueden acceder a la transmisión a través de la sección de relaciones con inversores del sitio web de Atossa. Para el acceso telefónico, los llamantes de EE. UU. deben marcar el 1-800-836-8184, mientras que los participantes internacionales pueden marcar el 1-646-357-8785. El nombre de la conferencia telefónica es 'Actualización Empresarial de Atossa Therapeutics'. Una repetición de 30 días estará disponible en el sitio web de la empresa después de la llamada.
Atossa Therapeutics (NASDAQ: ATOS), 유방암 약물에 중점을 둔 임상 단계의 생명공학 회사는 2025년 3월 25일 화요일 오전 8시 30분 ET에 2024년 4분기 및 연간 재무 결과에 대한 컨퍼런스 콜을 예정하고 있습니다.
회사는 기업 및 재무 결과에 대해 논의하기 위해 컨퍼런스 콜과 실시간 오디오 웹캐스트를 모두 진행할 예정입니다. 투자자들은 Atossa의 웹사이트 투자자 관계 섹션을 통해 웹캐스트에 접근할 수 있습니다. 전화 접속의 경우, 미국 전화자는 1-800-836-8184로 전화해야 하며, 국제 참가자는 1-646-357-8785로 전화할 수 있습니다. 컨퍼런스 콜의 이름은 'Atossa Therapeutics 비즈니스 업데이트'입니다. 콜 후 30일 동안 재생이 회사 웹사이트에서 제공될 예정입니다.
Atossa Therapeutics (NASDAQ: ATOS), une entreprise biopharmaceutique en phase clinique axée sur les médicaments contre le cancer du sein, a prévu une conférence téléphonique pour annoncer les résultats financiers du quatrième trimestre et de l'année entière 2024 pour le mardi 25 mars 2025, à 8h30 ET.
L'entreprise organisera à la fois une conférence téléphonique et un webinaire audio en direct pour discuter des résultats de l'entreprise et des finances. Les investisseurs peuvent accéder au webinaire via la section relations investisseurs du site Web d'Atossa. Pour l'accès téléphonique, les appelants américains doivent composer le 1-800-836-8184, tandis que les participants internationaux peuvent composer le 1-646-357-8785. Le nom de la conférence téléphonique est 'Mise à jour commerciale d'Atossa Therapeutics'. Un enregistrement de 30 jours sera disponible sur le site Web de l'entreprise après l'appel.
Atossa Therapeutics (NASDAQ: ATOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Medikamente gegen Brustkrebs konzentriert, hat eine Telefonkonferenz zur Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Dienstag, den 25. März 2025, um 8:30 Uhr ET angesetzt.
Das Unternehmen wird sowohl eine Telefonkonferenz als auch ein Live-Audio-Webcast veranstalten, um die Unternehmens- und Finanzergebnisse zu besprechen. Investoren können über den Bereich Investor Relations auf der Website von Atossa auf den Webcast zugreifen. Für den telefonischen Zugang sollten Anrufer aus den USA die Nummer 1-800-836-8184 wählen, während internationale Teilnehmer die Nummer 1-646-357-8785 wählen können. Der Name der Telefonkonferenz lautet 'Atossa Therapeutics Geschäftsinformationen'. Eine 30-tägige Wiederholung wird nach dem Anruf auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024.
The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
Contact
Michael Parks, VP Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
When will Atossa Therapeutics (ATOS) release Q4 and full-year 2024 earnings?
How can investors access ATOS's Q4 2024 earnings call?
How long will ATOS's Q4 2024 earnings call replay be available?
What will be discussed in Atossa Therapeutics' March 25 conference call?
